Some people in the company said that the fire point was an empty workshop where solvents were piled up, not an operation workshop. The reporter learned from the practitioners in the same industry that it is very common for Minolta to pile up solvents in the transit workshop.
"Because the solvent itself is flammable and explosive, many factories will choose to put it in a transit box alone before treating the waste solvent, and then dispose of it or recycle it to professional institutions." The person told reporters.
According to the 20021annual report, during the reporting period, Zhejiang minohua newly added two projects, namely "technical renovation and biogas boiler construction project of Zhejiang minohua pharmaceutical chemistry co., ltd." and "technical renovation and solvent recovery project of pharmaceutical raw materials of Zhejiang minohua pharmaceutical chemistry co., ltd.", which have passed the EIA approval. Shortly after the fire broke out, Novartis's share price fell.
The company is also one of the four production bases of Minova's bulk drug production capacity layout, located at No.8 Jingshan Road, Shangyu Economic and Technological Development Zone, Hangzhou Bay, producing L- carnosine and bulk drugs, including venlafaxine hydrochloride, valsartan, galanthamine hydrobromide, diphenhydramine hydrobromide and losartan potassium.
In 20021year, the company realized operating income of 4 1 1 billion yuan and net profit of 55,280,800 yuan. In 20021year, the total operating income of Novartis was 65.438+25.8 million yuan, up 5.43% year-on-year; The net profit attributable to shareholders of listed companies was 65.438+0.43 billion yuan, down 8.62% from the same period of last year; The net profit attributable to shareholders of listed companies after deducting non-operating gains and losses was 65.438+0.26 billion yuan, a year-on-year increase of 56.46%.
This means that Zhejiang Mennuohua's net profit last year accounted for nearly 40% of Mennuohua's net profit. Novartis's annual report shows that the company's investment in holding subsidiaries is still increasing.
According to the annual report, Mennohua invested in the first phase of Zhejiang Mennohua's "annual output of 520 tons of pharmaceutical raw materials" with self-raised funds, with a project amount of 350 million yuan. As of the release of the annual report, the main civil works have been basically completed, and the foundation of the tank farm has been completed. After the project is put into production, the estimated annual income can reach 600 million yuan.